BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18502835)

  • 21. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.
    Savage P; Gao L; Vento K; Cowburn P; Man S; Steven N; Ogg G; McMichael A; Epenetos A; Goulmy E; Stauss HJ
    Blood; 2004 Jun; 103(12):4613-5. PubMed ID: 14988155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.
    Schmidt SM; Schag K; Müller MR; Weinschenk T; Appel S; Schoor O; Weck MM; Grünebach F; Kanz L; Stevanovic S; Rammensee HG; Brossart P
    Cancer Res; 2004 Feb; 64(3):1164-70. PubMed ID: 14871853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
    Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
    Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
    Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
    J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
    Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
    Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of the WT1
    Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
    Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.
    Campos-Perez J; Rice J; Escors D; Collins M; Paterson A; Savelyeva N; Stevenson FK
    Int J Cancer; 2013 Sep; 133(6):1400-7. PubMed ID: 23494538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
    Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
    Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
    Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
    J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
    Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
    J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
    Rice J; Elliott T; Buchan S; Stevenson FK
    J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
    Alexander J; Oseroff C; Sidney J; Sette A
    Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.